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Establishing a robust two-step cloning strategy for the generation of cell lines with a
high probability of monoclonality
Alison Young1, Clare Lovelady1, Mahesh Shivare1, Jarka Glassey2, Shirley Coleman2,
Alison Porter1

1 Fujifilm Diosynth Biotechnologies, Billingham, UK
2 ISRU, Newcastle University, Newcastle UK

A regulatory requirement for the production of therapeutic proteins from mammalian
cells is that the production cell line is clonal, that is, derived from a single progenitor
cell. It is therefore standard procedure to include at least one cloning step during the
development of a recombinant cell line for therapeutic protein production. Numerous
techniques can be employed for cloning cell lines, but regardless of the cloning method
used there should be appropriate evidence to support that the method is fit for purpose.
A point highlighted by the increasing interest from regulatory bodies regarding the
cloning method used and the probability of monoclonality (P(monoclonality)) achieved
during cell line development (CLD).
FUJIFILM Diosynth Biotechnologies have thoroughly considered the cloning approach
used during CLD: A two-step cloning strategy employed which combines the
ClonePix™ as a cloning and screening tool followed by a second cloning step using
the industrially accepted method of limiting dilution cloning will be discussed. A
collaboration with statisticians led to the development of a method to estimate the
resulting P(monoclonality) of cell lines generated using the ClonePix™ and
experimental data to support this statistical method was generated, thereby ensuring
that the ClonePix™ cloning step is robust. We will highlight the challenges of using the
ClonePix™ for a single round of cloning and the advantages of combining it with a
second cloning step. We will demonstrate how we achieve a minimum probability of
monoclonality of ≥99.78% and typically achieve a P(monoclonality) of 99.9% using a
two-step cloning strategy.

